Form 4: Neogenomics Director Stephen Kanovsky Reports Vesting of RSUs and New Equity Grants

Neogenomics Inc. Director Stephen M. Kanovsky has reported the vesting of 12,254 restricted stock units into common stock and the acquisition of new stock options and restricted stock units as part of his compensation.

Summary

• Stephen M. Kanovsky, a Director at Neogenomics Inc. (NEO), reported changes in his beneficial ownership of company securities.
• On June 1, 2025, 12,254 restricted stock units (RSUs) previously held by Mr. Kanovsky vested and converted into 12,254 shares of Neogenomics Common Stock at a price of $0.
• Following this transaction, Mr. Kanovsky directly beneficially owns 52,344 shares of Common Stock.
• Additionally, on June 1, 2025, Mr. Kanovsky acquired new derivative securities:
• 16,107 stock options with an exercise price of $7.28, exercisable from June 1, 2026, and expiring on June 1, 2035.
• 23,077 restricted stock units (RSUs) with a conversion price of $0, exercisable from June 1, 2026.
• 8,672 stock options with an exercise price of $13.71, exercisable from June 1, 2025, and expiring on June 1, 2034.
• Mr. Kanovsky also holds several other stock options from previous grants with various exercise prices and expiration dates, totaling 58,445 stock options and 23,077 restricted stock units after the reported transactions.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it reflects routine compensation and continued alignment of a director's interests with the company through equity grants, without any negative implications or sales.

Positives

• The vesting of 12,254 restricted stock units at a $0 conversion price represents a direct increase in the director's common stock holdings, enhancing his direct equity stake in the company.
• The grant of new stock options (16,107 at $7.28 exercise price, 8,672 at $13.71 exercise price) and restricted stock units (23,077 units) indicates ongoing compensation and alignment of the director's interests with shareholder value.
• The continued equity grants suggest the company's commitment to retaining key leadership and incentivizing long-term performance.

Negatives

• The report does not contain any negative financial or operational information; it is a routine disclosure of insider equity transactions.

Future Outlook

This Form 4 filing does not provide forward-looking statements or guidance regarding the company's future financial performance or strategic outlook. It solely reports changes in insider beneficial ownership.

Industry Context

This filing is a routine disclosure of insider equity compensation and does not provide specific insights into broader industry trends or competitive landscape. It reflects standard practices for compensating corporate directors with equity.

Related Party Transactions

• The reported transactions represent equity compensation granted to a director, which is a common form of related party transaction intended to align management and board interests with shareholders.

Stakeholder Impact

• Shareholders: The issuance of new equity awards could lead to minor dilution, but it is a standard practice for incentivizing directors and aligning their interests with long-term shareholder value.
• Director (Stephen M. Kanovsky): The transactions increase his direct equity stake and provide future potential value through exercisable options and RSUs, serving as a form of compensation and retention.

Next Steps

• The newly granted stock options will become exercisable on June 1, 2026, and the new restricted stock units will also become exercisable on June 1, 2026.

Key Dates

Keywords

Neogenomics Inc., NEO, SEC Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, Stock Options, Equity Compensation, Director Compensation, Stephen M. Kanovsky